While many farmers have already purchased fertiliser for this season, there will be some who haven’t been able to do that, ...
Although many things can affect your individual prognosis, about half of all patients will reach kidney failure within 10 years of their diagnosis and need dialysis or a kidney transplant. Even after ...
What Is Sotyktu, and Why Does It Matter? Sotyktu (deucravacitinib) is an oral selective tyrosine kinase 2 (TYK2) inhibitor used to treat autoimmune inflammatory diseases such as plaque psoriasis in ...
Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
FDA sNDAs seek approval of belzutifan plus lenvatinib for post–PD-1/PD-L1 advanced ccRCC, setting an October 4, 2026 PDUFA target action date. LITESPARK-011 randomized 747 patients to belzutifan 120 ...
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results